Biomedical Engineering Reference
In-Depth Information
88. Matthews EJ, Kruhlak NL, Daniel Benz R, Sabat´ DA, Marchant CA, Contrera JF (2009)
Identification of structure-activity relationships for adverse effects of pharmaceuticals in
humans: Part C: use of QSAR and an expert system for the estimation of the mechanism of
action of drug-induced hepatobiliary and urinary tract toxicities. Regul Toxicol Pharmacol
54:43-65
89. Cavalli A, Poluzzi E, De Ponti F, Recanatini M (2002) Toward a pharmacophore for drugs
inducing the long QT syndrome: insights from a CoMFA Study of HERG K+ channel
blockers. J Med Chem 45:3844-3853
90. Furutani K, Ohno Y, Inanobe A, Hibino H, Kurachi Y (2009) Mutational and in silico
analyses for antidepressant block of astroglial
inward-rectifier Kir4.1 channel. Mol
Pharmacol 75:1287-1295
91. Satuluri VSAK, Seelam J, Gupta SP (2009) A quantitative structure-activity relationship
study on some series of potassium channel blockers. Med Chem 5:87-92
92. Furutani K, Hibino H, Inanobe A, Kurachi Y (2009) Compound-induced block of ion channel
pore function:
inward-rectifier potassium channels as a model. Mol Cell Pharmacol
75:1287-1295
93. van de Waterbeemd H (2008) Introduction. Advanced Computer-Assisted Techniques in
Drug Discovery, Wiley-VCH Verlag GmbH
94. Yoshida K, Niwa T (2006) Quantitative structure - activity relationship studies on inhibition
of HERG potassium channels. J Chem Inf Model 46:1371-1378
95. Song M, Clark M (2005) Development and evaluation of an in silico model for hERG
binding. J Chem Inf Model 46:392-400
96. Shamovsky I, de Graaf C, Alderin L, Bengtsson M, Bladh H, Borjesson L, Connolly S, Dyke
HJ, van den Heuvel M, Johansson H, Josefsson B-G, Kristoffersson A, Linnanen T, Lisius A,
Mannikko R, Norden B, Price S, Ripa L, Rognan D, Rosendahl A, Skrinjar M, Urbahns K
(2009) Increasing selectivity of CC chemokine receptor 8 antagonists by engineering
nondesolvation related interactions with the intended and off-target binding sites. J Med
Chem 52:7706-7723
97. Perkins R, Fang H, Tong W, Welsh WJ (2003) Quantitative structure-activity relationship
methods: perspectives on drug discovery and toxicology. Environ Toxicol Chem
22:1666-1679
98. Carrieri A, Muraglia M, Corbo F, Pacifico C (2009) 2D- and 3D-QSAR of Tocainide and
Mexiletine analogues acting as Nav1.4 channel blockers. Eur J Med Chem 44:1477-1485
99. Mungalpara J, Pandey A, Jain V, Mohan C (2010) Molecular modelling and QSAR analysis
of some structurally diverse N-type calcium channel blockers. J Mol Model 16:629-644
100. Su B-H, M-y S, Esposito EX, Hopfinger AJ, Tseng YJ (2010) In silico binary classification
QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG
blockage. J Chem Inf Model 50:1304-1318
101. Vedani A, Briem H, Dobler M, Dollinger H, McMasters DR (2000) Multiple-conformation
and protonation-state representation in 4D-QSAR: the neurokinin-1 receptor system. J Med
Chem 43:4416-4427
102. Krasowski MD, Hong X, Hopfinger AJ, Harrison NL (2002) 4D-QSAR analysis of a set of
propofol analogues: mapping binding sites for an anesthetic phenol on the GABAA receptor.
J Med Chem 45:3210-3221
103. Ekins S, Kortagere S, Iyer M, Reschly EJ, Lill MA, Redinbo MR, Krasowski MD (2009)
Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear
receptor PXR. PLoS Comput Biol 5:e1000594
104. Klein CDP, Hopfinger AJ (1998) Pharmacological activity and membrane interactions of
antiarrhythmics: 4D-QSAR/QSPR analysis. Pharm Res 15:303-311
105. van de Waterbeemd H, Gifford E (2003) ADMET in silico modelling: towards prediction
paradise? Nat Rev Drug Discov 2:192-204
106. Shaikh SA, Jain T, Sandhu G, Latha N, Jayaram B (2007) From drug target to leads-sketching
a physicochemical pathway for lead molecule design in silico. Curr Pharm Des 13:3454-3470
